After criticisms, Biogen slashes price of its Alzheimer drug in half

Biogen is slashing the price of its Alzheimer's treatment in half, months after it debuted to widespread criticism for an initial cost that could reach $56,000 annually.

Aduhelm, the first new FDA-approved Alzheimer's drug in almost two decades, is the first in a line of new drugs that promise to do what no other Alzheimer's treatment has managed: Slow the progress of the fatal brain-destroying disease, rather than just managing its symptoms. 

The drugmaker said Monday it will cut the wholesale acquisition cost of the drug by about 50% next month. That means the annual cost for a person of average weight will amount to $28,200.